NCT00683059View on ClinicalTrials.gov

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Transitional Cell Carcinoma
Interventions
DRUG

Paclitaxel

total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.

Trial Locations (5)

L8V 5C2

Juravinski Cancer Centre, Hamilton

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Regional Cancer Centre, Ottawa

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER